Caribou Biosciences

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Caribou Biosciences (CRBU) gets a major boost with a $25 million equity investment by Pfizer, which will accelerate the development of its allogeneic CAR-T cell therapy pipeline.

Caribou Biosciences (CRBU) Soars on $25M Investment by Pfizer

Caribou Biosciences, Inc. (CRBU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Caribou Biosciences, Inc. (CRBU) Surges 45.6%: Is This an Indication of Further Gains?

Affirm

Here are three of today's notable movers, as the  broader market  takes a tumble following this morning's flood of economic data.

3 Stocks Moving Today: CRBU, META, AFRM

Caribou is a clinical-stage biotech that specializes in CRISPR gene-editing therapies. Caribou said it had $291 million in cash at the end of the first quarter.

Why Shares of Caribou Biosciences Are Skyrocketing Today

Caribou Biosciences (NASDAQ: CRBU ) stock is taking off on Thursday after the gene-editing company announced an investment from Pfizer (NYSE: PFE ). Caribou Biosciences reports that Pfizer has made a $25 million equity investment in the company.

The $25 Million Reason Caribou Biosciences (CRBU) Stock Is Soaring Today

Pfizer

Pfizer has invested $25 million to buy a minority stake in Caribou Biosciences , making it the latest small biotechnology firm to attract the pharmaceutical giant's interest.

Pfizer makes equity investment in Caribou Biosciences

Shares of Caribou Biosciences Inc. CRBU ran up 21.3% toward a three-month high in premarket trading Thursday, after the genome-editing biopharmaceutical company said drug giant Pfizer Inc. has made a $25 million equity investment in the company. Pfizer shares slipped 0.1% ahead of the open.

Caribou Biosciences stock soars after Pfizer buys stock priced at a 31% premium

-- Pfizer purchases $25 million of Caribou common shares -- -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou's Scientific Advisory Board --

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Caribou Biosciences, Inc. (NASDAQ: CRBU) on behalf of long-term stockholders following a class action complaint that was filed against Caribou on April 11, 2023 with a Class Period from July 23, 2021 to December 9, 2022, or pursuant to the Company's July 2021 IPO. Our investigation concerns whether the board of directors of Caribou have breac.

CARIBOU ALERT: Bragar Eagel & Squire, P.C. is Investigating Caribou Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.35 per share a year ago.

Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Lags Revenue Estimates

-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1 --

Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

-- Dr. Schuster is a world-renowned hematologist and pioneer in  CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the appointment of Stephen J. Schuster, MD, to its scientific advisory board (SAB). Dr. Schuster is an expert in treating patients with lymphoma and developing novel treatments, including pioneering the development of chimeric antigen receptor (CAR)-T cell therapies.

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

-- CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models -- -- CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 --

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting

NEW YORK , April 11, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU) alleging that the Company violated federal securities laws.

CRBU ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 11, 2023 in the Class Action Filed on Behalf of Caribou Biosciences, Inc. Shareholders

NEW YORK , April 10, 2023 /PRNewswire/ -- Attention Caribou Biosciences, Inc. ("Caribou") (NASDAQ: CRBU) shareholders:

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Caribou Investors of a Lead Plaintiff Deadline of April 11, 2023

NEW YORK , April 6, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or traceable to the offering documents and related prospectus issued in connection with the Company's 2021 initial public offering conducted on or about July 23, 2021 (the "IPO" or "Offering"); and/or (ii) between July 23, 2021 and December 9, 2022, both dates inclusive (the "Class Period"), of the important April 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

CRBU IMPORTANT DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 11 Deadline in Securities Class Action - CRBU

NEW YORK , April 5, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Caribou Biosciences, Inc. Shareholders who purchased shares of CRBU during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Caribou Biosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 11, 2023 - (NASDAQ: CRBU)

-- CaMMouflage Phase 1 trial for CB-011 enrolling patients with r/r MM at dose level 1 -- BERKELEY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CB-011, which is being developed for relapsed or refractory multiple myeloma (r/r MM). CB-011 is being evaluated in the company's ongoing CaMMouflage Phase 1 clinical trial in patients with r/r MM.

Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma

NEW YORK , March 31, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Caribou Biosciences, Inc. (NASDAQ: CRBU). To receive updates on the lawsuit, fill out the form: https://claimyourloss.com/securities/caribou-biosciences-inc-loss-submission-form/?id=37900&from=4 This lawsuit is on behalf of persons and entities that purchased or otherwise acquired: (a) Caribou common stock pursuant and/or traceable to documents issued in connection with the Company's initial public offering conducted on or about July 23, 2021; and/or (b) Caribou securities between July 23, 2021, and December 9, 2022.

CRBU SHAREHOLDER ALERT: Jakubowitz Law Reminds Caribou Shareholders of a Lead Plaintiff Deadline of April 11, 2023

NEW YORK , March 30, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Caribou Biosciences, Inc. ("Caribou" or the "Company") (NASDAQ: CRBU) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Caribou investors who were adversely affected by alleged securities fraud.

CRBU LAWSUIT ALERT: Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , March 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or traceable to the offering documents and related prospectus issued in connection with the Company's 2021 initial public offering conducted on or about July 23, 2021 (the "IPO" or "Offering"); and/or (ii) between July 23, 2021 and December 9, 2022, both dates inclusive (the "Class Period"), of the important April 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

Did you lose money on investments in Caribou Biosciences? If so, please visit Caribou Biosciences, Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

CARIBOU BIOSCIENCES, INC. (NASDAQ: CRBU) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Caribou Biosciences, Inc. (NASDAQ: CRBU)

NEW YORK , March 16, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or traceable to the offering documents and related prospectus issued in connection with the Company's 2021 initial public offering conducted on or about July 23, 2021 (the "IPO" or "Offering"); and/or (ii) between July 23, 2021 and December 9, 2022, both dates inclusive (the "Class Period"), of the important April 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of 6.38% and 2.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Misses Revenue Estimates

NEW YORK , March 9, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of Caribou Biosciences, Inc. (NASDAQ: CRBU): (i) pursuant and/or traceable to the offering documents and related prospectus issued in connection with the Company's 2021 initial public offering conducted on or about July 23, 2021 (the "IPO" or "Offering"); and/or (ii) between July 23, 2021 and December 9, 2022, both dates inclusive (the "Class Period"), of the important April 11, 2023 lead plaintiff deadline. SO WHAT: If you purchased Caribou securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A LONGSTANDING LAW FIRM, Encourages Caribou Biosciences, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - CRBU

News for Caribou Biosciences Stock (CRBU)